Cargando…

Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies

The abnormal accumulation of α-Synuclein (α-Syn) is a prominent pathological feature in a group of diseases called α-Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The formation of Lewy bodies (LBs) and glial cytoplasmic inclusions...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemos, Miguel, Stefanova, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518386/
https://www.ncbi.nlm.nih.gov/pubmed/33041780
http://dx.doi.org/10.3389/fnsyn.2020.586453
_version_ 1783587388053782528
author Lemos, Miguel
Stefanova, Nadia
author_facet Lemos, Miguel
Stefanova, Nadia
author_sort Lemos, Miguel
collection PubMed
description The abnormal accumulation of α-Synuclein (α-Syn) is a prominent pathological feature in a group of diseases called α-Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The formation of Lewy bodies (LBs) and glial cytoplasmic inclusions (GCIs) in neurons and oligodendrocytes, respectively, is highly investigated. However, the molecular mechanisms behind α-Syn improper folding and aggregation remain unclear. Histone deacetylase 6 (HDAC6) is a Class II deacetylase, containing two active catalytic domains and a ubiquitin-binding domain. The properties of HDAC6 and its exclusive cytoplasmic localization allow HDAC6 to modulate the microtubule dynamics, acting as a specific α-tubulin deacetylase. Also, HDAC6 can bind ubiquitinated proteins, facilitating the formation of the aggresome, a cellular defense mechanism to cope with higher levels of misfolded proteins. Several studies report that the aggresome shares similarities in size and composition with LBs and GCIs. HDAC6 is found to co-localize with α-Syn in neurons and in oligodendrocytes, together with other aggresome-related proteins. The involvement of HDAC6 in several neurodegenerative diseases is already under discussion, however, the results obtained by modulating HDAC6 activity are not entirely conclusive. The main goal of this review is to summarize and critically discuss previous in vitro and in vivo data regarding the specific role of HDAC6 in the context of α-Syn accumulation and protein aggregation in α-Synucleinopathies.
format Online
Article
Text
id pubmed-7518386
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75183862020-10-09 Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies Lemos, Miguel Stefanova, Nadia Front Synaptic Neurosci Neuroscience The abnormal accumulation of α-Synuclein (α-Syn) is a prominent pathological feature in a group of diseases called α-Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The formation of Lewy bodies (LBs) and glial cytoplasmic inclusions (GCIs) in neurons and oligodendrocytes, respectively, is highly investigated. However, the molecular mechanisms behind α-Syn improper folding and aggregation remain unclear. Histone deacetylase 6 (HDAC6) is a Class II deacetylase, containing two active catalytic domains and a ubiquitin-binding domain. The properties of HDAC6 and its exclusive cytoplasmic localization allow HDAC6 to modulate the microtubule dynamics, acting as a specific α-tubulin deacetylase. Also, HDAC6 can bind ubiquitinated proteins, facilitating the formation of the aggresome, a cellular defense mechanism to cope with higher levels of misfolded proteins. Several studies report that the aggresome shares similarities in size and composition with LBs and GCIs. HDAC6 is found to co-localize with α-Syn in neurons and in oligodendrocytes, together with other aggresome-related proteins. The involvement of HDAC6 in several neurodegenerative diseases is already under discussion, however, the results obtained by modulating HDAC6 activity are not entirely conclusive. The main goal of this review is to summarize and critically discuss previous in vitro and in vivo data regarding the specific role of HDAC6 in the context of α-Syn accumulation and protein aggregation in α-Synucleinopathies. Frontiers Media S.A. 2020-09-11 /pmc/articles/PMC7518386/ /pubmed/33041780 http://dx.doi.org/10.3389/fnsyn.2020.586453 Text en Copyright © 2020 Lemos and Stefanova. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Lemos, Miguel
Stefanova, Nadia
Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
title Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
title_full Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
title_fullStr Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
title_full_unstemmed Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
title_short Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
title_sort histone deacetylase 6 and the disease mechanisms of α-synucleinopathies
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518386/
https://www.ncbi.nlm.nih.gov/pubmed/33041780
http://dx.doi.org/10.3389/fnsyn.2020.586453
work_keys_str_mv AT lemosmiguel histonedeacetylase6andthediseasemechanismsofasynucleinopathies
AT stefanovanadia histonedeacetylase6andthediseasemechanismsofasynucleinopathies